Versant Ventures
VC Fund
Menlo Park, United States
Versant Ventures is a healthcare investment firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firm invests across the healthcare sector and at all stages of company development, with an emphasis on the discovery and development of novel therapeutics. With $2.3 billion under management and offices in Canada, the U.S., and Europe, Versant has built a team with deep investment, operating, and scientific expertise that enables a hands-on approach to company building. Since the firm’s founding in 1999, more than 65 Versant companies have achieved successful acquisitions or IPOs.
- Total investments:
- 334
- Last investment:
- Lead investor:
- 31%
- Fund size:
- $5M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Versant Ventures invests in
Stages Versant Ventures invests in
Countries Versant Ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 19 contacts → | |||
Round size
- Series A
- $5M–$78M
- Series B
- $12M–$105M
- Series C
- $12M–$107M
Investment Focus
Industry
- Biotechnology 122 (37%)
- Health Care 116 (35%)
- Medical 59 (18%)
- Therapeutics 50 (15%)
- Medical Device 40 (12%)
Stage
- Series A 90 (27%)
- Series B 76 (23%)
- Series C 49 (15%)
- Series D 26 (8%)
- Funding Round 17 (5%)
Country
- United States 138 (41%)
- Switzerland 13 (4%)
- Canada 5 (1%)
- France 2 (1%)
- China 1 (0%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Clare Ozawa
Managing Director
|
Managing Director | Total investments: 13 | Find email | |
Donald Milder
Managing Director
|
Managing Director | Total investments: 2 | Find email | |
Gianni Gromo
Partner
|
Partner | Total investments: 2 | Find email | |
Guido Magni
Partner
|
Partner | Total investments: 7 | Find email | |
Max Eisenberg
General Counsel
|
General Counsel | Total investments: 0 | Find email | |
| See all 19 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Dayra Therapeutics manufactures peptide based medicines. | $20M / Venture - Series Unknown / Nov 24, 2025 | ||
| Gate Bioscience specializes in a small molecule modality to treat biology’s intractable diseases. | $65M / Series B / Nov 13, 2025 | ||
| Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline | $65M / Series A / Sep 16, 2025 | ||
| AllRock Bio is a drug developing firm that offers novel therapies to patients suffering hypertension and other fibrotic conditions. | $50M / Series A / Sep 16, 2025 | ||
| Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases. We target conditions where the underlying biology is well-understood, rationally designing one-time gene therapies to durably express therapeutic proteins within the appropriate humantissues. Our team has deep expertise in the field and includes former senior leadership from pioneering gene therapy companies and academic institutions. We use algorithmic tools, scalable infrastructure, and proprietary technology to optimize the efficacy and durability of our gene therapies – with a goal of transforming the treatment paradigm for some of the most serious and widespread diseases. | $313.3M / Series C / Aug 15, 2025 | ||
| Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders. | $30M / Series A / Apr 24, 2025 | ||
| Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders. | $65M / Series A / Jan 28, 2025 | ||
| Light Horse Therapeutics is the gene editing applied to small-molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases. Its advanced platform identifies cryptic chemically accessible functional domains within targets that are critical in disease biology. Our initial focus addresseshigh-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future. | $62M / Series A / Jan 09, 2025 | ||
| Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner. | $84.1M / Series A / Dec 04, 2024 | ||
Pep2Tango Therapeutics
|
Pep2Tango Therapeutics is a biotechnology company that offers superior unimolecular multi-receptor drugs for obesity and related disorders. | $1K / Venture - Series Unknown / Nov 21, 2024 | |
| See all 334 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Versant Ventures invest in?
Versant Ventures invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 334 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Versant Ventures invest in?
Versant Ventures typically joins rounds of $5M–$78M at Series A, $12M–$105M at Series B and $12M–$107M at Series C. These are whole funding-round sizes, not Versant Ventures's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Versant Ventures took part in.
How do I contact Versant Ventures?
Public channels for Versant Ventures include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Versant Ventures?
The team at Versant Ventures includes Clare Ozawa (Managing Director), Donald Milder (Managing Director) and Gianni Gromo (Partner), among 19 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
